Biogen Inc (BIIB)
Industry Drug Manufacturers - General
This stock can be held in an Investment ISA and an Investment Account
Sell
$124.04
Buy
$124.16
$5.92 (+5.01%)
Prices updated at 12 May 2025, 18:09 EDT
| Prices minimum 15 mins delay
Prices in USD
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
---|---|---|
9,836m | 9,676m | |
7,302m | 7,366m | |
1,831m | 2,219m | |
18.62 | 22.93 | |
1,161m | 1,632m | |
2,039m | 2,830m | |
Sales, General and administrative | 2,550m | 2,404m |
Interest expenses | 247m | 250m |
Provision for income taxes | 135m | 274m |
Operating expenses | 5,471m | 5,147m |
Income before taxes | 1,297m | 1,906m |
Net income available to common shareholders | 1,161m | 1,632m |
8.02 | 11.21 | |
Net interest income | 30m | -183m |
Advertising and promotion | - | - |
Net investment income, net | - | - |
Realised capital gains (losses), net | - | - |
Total benefits, claims and expenses | - | - |
Earnings per share (diluted) | 7.97 | 11.18 |
Free cash flow per share | 7.0534 | 12.1144 |
Book value/share | 99.9572 | 112.2631 |
Debt equity ratio | 0.485709 | 0.292038 |
Balance sheet
Year | 2023 | 2024 |
---|---|---|
Current assets | 6,859m | 7,457m |
Current liabilities | 3,434m | 5,529m |
Total capital | 21,588m | 21,263m |
Total debt | 7,338m | 6,630m |
Total equity | 14,799m | 16,716m |
Total non current liabilities | - | - |
Loans | 6,788m | 4,547m |
Total assets | 26,845m | 28,049m |
Total liabilities | - | - |
Cash and cash equivalents | 1,050m | 2,375m |
Common stock | 145m | 146m |
Cash flow
Year | 2023 | 2024 |
---|---|---|
Cash at beginning of period | 3,419m | 1,050m |
Cash dividends paid | - | - |
1,236m | 2,516m | |
Investments (gains) losses | -4,101m | -799m |
1,050m | 2,375m | |
Net income | - | - |
1,547m | 2,876m | |
-311m | -360m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.